Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Ardizzoni

Showing results (11-20 of 369) with videos related to

Pageof 37
Sort By:
Investigational New Drugs|June 21, 2017
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse eventFrancesco Gelsomino, Giovanni Vitale, Andrea Ardizzoni
Journal of Thoracic Disease|June 1, 2018
Is the door open to further investigation with antiangiogenesis in SCLC?Marcello Tiseo, Luca Boni, Andrea Ardizzoni
The New England Journal of Medicine|July 19, 2013
Colony-stimulating factors for febrile neutropeniaSebastiano Buti, Angelica Sikokis, Andrea Ardizzoni
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?Marcello Tiseo, Andrea Ardizzoni, Luca Boni
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2015
Second-line Treatment of Small Cell Lung Cancer: Is Platinum Sensitivity a Relevant Prognostic Factor?Marcello Tiseo, Luca Boni, Andrea Ardizzoni
Frontiers in Microbiology|June 24, 2021
It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled With <i>Candida</i> Virulence, Triggers VVC OnsetAndrea Ardizzoni, Robert T Wheeler, Eva Pericolini
European Urology|November 8, 2017
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8Francesco Massari, Vincenzo Di Nunno, Andrea Ardizzoni
Oncology Reviews|May 21, 2015
Systemic adjuvant therapies in renal cell carcinomaSebastiano Buti, Melissa Bersanelli, Maddalena Donini, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|March 23, 2004
Farnesylated proteins as anticancer drug targets: from laboratory to the clinicPatrizia Russo, Maura Loprevite, Alfredo Cesario, et al.
Expert Review of Anticancer Therapy|April 21, 2009
First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtypeMarcello Tiseo, Marco Bartolotti, Francesco Gelsomino, et al.
Pageof 37

Showing results (11-20 of 369) with videos related to

Sort By:
Pageof 37
Investigational New Drugs|June 21, 2017
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse eventFrancesco Gelsomino, Giovanni Vitale, Andrea Ardizzoni
Journal of Thoracic Disease|June 1, 2018
Is the door open to further investigation with antiangiogenesis in SCLC?Marcello Tiseo, Luca Boni, Andrea Ardizzoni
The New England Journal of Medicine|July 19, 2013
Colony-stimulating factors for febrile neutropeniaSebastiano Buti, Angelica Sikokis, Andrea Ardizzoni
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?Marcello Tiseo, Andrea Ardizzoni, Luca Boni
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2015
Second-line Treatment of Small Cell Lung Cancer: Is Platinum Sensitivity a Relevant Prognostic Factor?Marcello Tiseo, Luca Boni, Andrea Ardizzoni
Frontiers in Microbiology|June 24, 2021
It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled With <i>Candida</i> Virulence, Triggers VVC OnsetAndrea Ardizzoni, Robert T Wheeler, Eva Pericolini
European Urology|November 8, 2017
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8Francesco Massari, Vincenzo Di Nunno, Andrea Ardizzoni
Oncology Reviews|May 21, 2015
Systemic adjuvant therapies in renal cell carcinomaSebastiano Buti, Melissa Bersanelli, Maddalena Donini, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|March 23, 2004
Farnesylated proteins as anticancer drug targets: from laboratory to the clinicPatrizia Russo, Maura Loprevite, Alfredo Cesario, et al.
Expert Review of Anticancer Therapy|April 21, 2009
First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtypeMarcello Tiseo, Marco Bartolotti, Francesco Gelsomino, et al.
Pageof 37